The DOI matches its Crossref record.
Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor.
Open accessAbstract
Experimental allergic encephalomyelitis (EAE) is an autoimmune disease of the central nervous system that serves as a model for the human disease multiple sclerosis. We evaluated rolipram, a type IV phosphodiesterase inhibitor, for its efficacy in preventing EAE in the common marmoset Callithrix jacchus. In a blinded experimental design, clinical signs of EAE developed within 17 days of immunization with human white matter in two placebo-treated animals but in none of three monkeys that received rolipram (10 mg/kg s.c. every other day) beginning 1 week after immunization. In controls, signs of EAE were associated with development of cerebrospinal fluid pleocytosis and cerebral MRI abnormalities. In the treatment group, there was sustained protection from clinical EAE, transient cerebrospinal fluid pleocytosis in only one of three animals, no MRI abnormality, and marked reduction in histopathologic findings. Rolipram-treated and control animals equally developed circulating antibodies to myelin basic protein. Thus, inhibition of type IV phosphodiesterase, initiated after sensitization to central nervous system antigens, protected against autoimmune demyelinating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Elenkov, I. J., Wilder, R. L., Chrousos, G. P., & Vizi, E. S. (2000) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01470-4 · Cited by 2,252
van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., von Blomberg, B. M. E., Woody, J. N., Hartung, H.-P., & Polman, C. H. (1996) · Neurology · doi:10.1212/wnl.47.6.1531 · Cited by 733
Microglia as effector cells in brain damage and repair: focus on prostanoids and nitric oxide
Minghetti, L. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(97)00052-x · Cited by 567
An Interleukin (IL)-10/IL-12 Immunoregulatory Circuit Controls Susceptibility to Autoimmune Disease
Segal, B. M., Dwyer, B. K., & Shevach, E. M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.4.537 · Cited by 469
Angeles Muñoz-Fernández, M., & Fresno, M. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00045-8 · Cited by 367
Beeton, C., Wulff, H., Barbaria, J., Clot-Faybesse, O., Pennington, M., Bernard, D., Cahalan, M. D., Chandy, K. G., & Béraud, E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241497298 · Cited by 318
Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate.
Genain, C. P., Nguyen, M. H., Letvin, N. L., Pearl, R., Davis, R. L., Adelman, M., Lees, M. B., Linington, C., & Hauser, S. L. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118368 · Cited by 314
Self-citationRaine, C. S., Cannella, B., Hauser, S. L., & Genain, C. P. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199908)46:2<144::aid-ana3>3.0.co;2-k · Cited by 286
Self-citationCyclic-3′,5′-nucleotide phosphodiesterase isozymes in cell biology and pathophysiology of the kidney
Dousa, T. P. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00233.x · Cited by 274
Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis
Steinman, L., & Zamvil, S. S. (2005) · Trends in Immunology · doi:10.1016/j.it.2005.08.014 · Cited by 265
Ito, A., Bebo, B. F., Matejuk, A., Zamora, A., Silverman, M., Fyfe-Johnson, A., & Offner, H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.542 · Cited by 254
Franklin, K. M., Hauser, S. R., Lasek, A. W., McClintick, J., Ding, Z.-M., McBride, W. J., & Bell, R. L. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3852-3 · Cited by 44
“Since inhibition of PDE4 will result in the reduction of inflammatory and apoptotic responses (Genain et al. 1995; Sekut et al. 1995; Souness et al. 2000; Teixeira et al. 1997; Sousa et al. 2010) , the findings suggest that pro-inflammatory and apoptotic neuroimmune system responses to EtOH…”
Self-citation
Metadata
- Authors
- Genain, C. P., Roberts, T., Davis, R. L., Nguyen, M. H., Uccelli, A., Faulds, D., Li, Y., Hedgpeth, J., & Hauser, S. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1995-04-11
- Volume
- 92
- Issue
- 8
- Pages
- 3601-3605
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2080324970
- Cited by
- 178
- References
- 0
- FWCI
- 16.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.